Mupirocina Infectopharm

Mupirocin, the active ingredient in Mupirocina Infectopharm, is a monoxycarbolic acid antibiotic presented as a nasal ointment for nasal use. It treats bacterial colonisation of the nasal passages, particularly Staphylococcus aureus, in both adults and children.

GNH USA supplies Mupirocina Infectopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for bulk and packaged forms across multiple regions, including Europe, Asia and the Americas globally.

Mupirocin is a topical antibacterial agent used to eradicate nasal colonisation of Staphylococcus aureus.

- Nasal carriage of Staphylococcus aureus: eliminates bacterial colonisation and reduces risk of subsequent infection. - Pre‑surgical decolonisation: prepares patients for surgery by removing nasal MRSA, lowering postoperative infection rates. - Prevention of recurrent skin infections: reduces recurrence in carriers by clearing nasal reservoirs.

Mupirocin nasal ointment may cause local and, rarely, systemic adverse reactions.

Common Side Effects: - Nasal irritation: mild burning or stinging at the application site. - Itching: localized pruritus in the nasal mucosa. - Dryness: sensation of dryness inside the nose.

Serious or Rare Side Effects: - Allergic contact dermatitis: redness, swelling, and rash requiring medical attention. - Anaphylaxis: severe systemic allergic reaction with difficulty breathing or hypotension. - Stevens‑Johnson syndrome: severe skin reaction that may involve mucous membranes.

When using Mupirocina Infectopharm, consider the following precautions. - Pregnancy: safety not established; use only if clearly needed. - Breastfeeding: limited data; weigh risk versus benefit. - Age restrictions: not recommended for infants under 2 months without medical supervision. - Concomitant antibiotics: may reduce effectiveness if systemic antibiotics target the same organisms. - Resistance: avoid prolonged use to prevent bacterial resistance development. - Store at below 25°C: keep in original container, protect from moisture and light.

Mupirocina Infectopharm may interact with other medicines.

Major Interactions (Avoid): - Systemic antibiotics with overlapping spectrum (e.g., oral clindamycin): may diminish mupirocin’s local efficacy. - Topical nasal decongestants or steroids: increase risk of irritation and reduced absorption.

Moderate Interactions (Monitor Closely): - Other topical antibiotics (e.g., bacitracin): potential additive irritation. - Antifungal nasal preparations: may alter local flora. - Immunosuppressive therapy: heightened risk of infection despite treatment.